Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Brainstorm Cell Therapeutics Inc (BCLI) USD0.00005

Sell:$3.95 Buy:$3.99 Change: $0.07 (1.72%)
NASDAQ:0.74%
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Sell:$3.95
Buy:$3.99
Change: $0.07 (1.72%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Sell:$3.95
Buy:$3.99
Change: $0.07 (1.72%)
Market closed |  Prices as at close on 19 July 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

Contact details

Address:
1325 Avenue of the Americas Fl 28
NEW YORK
10019-6583
United States
Telephone:
+1 (201) 4880460
Website:
www.brainstorm-cell.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCLI
ISIN:
US10501E2019
Market cap:
$86.60 million
Shares in issue:
21.70 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Irit Arbel
    Independent Chairman of the Board
  • Chaim Lebovits
    President, Chief Executive Officer
  • Eyal Rubin
    Chief Financial Officer, Treasurer
  • Ralph Kern
    Chief Operating Officer and Chief Medical Officer
  • Uri Yablonka
    Executive Vice President, Chief Business Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.